OptimizeRx Corp (OPRX) › Cash & EquivalentsOptimizeRx Corp (OPRX) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2010-12-31: $1.28M2011-12-31: $959.2K2012-12-31: $284.3K2013-12-31: $1.12M2014-12-31: $3.45M2015-12-31: $8.21M2016-12-31: $7.03M2017-12-31: $5.12M2018-12-31: $8.91M2019-12-31: $18.85M2020-12-31: $10.52M2021-12-31: $84.68M2022-12-31: $18.21M2023-12-31: $13.85M2024-12-31: $13.38M2025-12-31: $23.36M$23.36M2010-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$23.36M+74.6%2026-03-12Balance as of period end2024-12-31$13.38M-3.4%2026-03-12Balance as of period end2023-12-31$13.85M-23.9%2025-03-20Balance as of period end2022-12-31$18.21M-78.5%2024-04-15Balance as of period end2021-12-31$84.68M+705.2%2023-03-10Balance as of period end2020-12-31$10.52M-44.2%2023-03-10Balance as of period end2019-12-31$18.85M+111.5%2021-03-08Balance as of period end2018-12-31$8.91M+74.0%2021-03-08Balance as of period end2017-12-31$5.12M-27.2%2020-03-26Balance as of period end2016-12-31$7.03M-14.3%2019-03-12Balance as of period end2015-12-31$8.21M+138.1%2018-03-08Balance as of period end2014-12-31$3.45M+208.2%2017-03-08Balance as of period end2013-12-31$1.12M+293.4%2016-03-15Balance as of period end2012-12-31$284.3K-70.4%2015-09-16Balance as of period end2011-12-31$959.2K-25.0%2013-03-12Balance as of period end2010-12-31$1.28M—2012-03-30Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)